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Abstract
Background: The carboxyl terminal of Epstein-Barr virus (EBV) ZEBRA protein (also termed BZLF-1 encoded
replication protein Zta or ZEBRA) binds to both NF-B and p53. The authors have previously suggested that this
interaction results from an ankyrin-like region of the ZEBRA protein since ankyrin proteins such as IB interact with
NF-B and p53 proteins. These interactions may play a role in immunopathology and viral carcinogenesis in B
lymphocytes as well as other cell types transiently infected by EBV such as T lymphocytes, macrophages and
epithelial cells.
Methods: Randomization of the ZEBRA terminal amino acid sequence followed by statistical analysis suggest that
the ZEBRA carboxyl terminus is most closely related to ankyrins of the invertebrate cactus IB-like protein. This
observation is consistent with an ancient origin of ZEBRA resulting from a recombination event between an
ankyrin regulatory protein and a fos/jun DNA binding factor. In silico modeling of the partially solved ZEBRA
carboxyl terminus structure using PyMOL software demonstrate that the carboxyl terminus region of ZEBRA can
form a polymorphic structure termed ZANK (ZEBRA ANKyrin-like region) similar to two adjacent IB ankyrin
domains.
Conclusions: Viral capture of an ankyrin-like domain provides a mechanism for ZEBRA binding to proteins in the
NF-B and p53 transcription factor families, and also provides support for a process termed “Ping-Pong Evolution”
in which DNA viruses such as EBV are formed by exchange of information with the host genome. An amino acid
polymorphism in the ZANK region is identified in ZEBRA from tumor cell lines including Akata that could alter
binding of Akata ZEBRA to the p53 tumor suppressor and other ankyrin binding protein, and a novel model of
antagonistic binding interactions between ZANK and the DNA binding regions of ZEBRA is suggested that may be
explored in further biochemical and molecular biological models of viral replication.
Keywords: p53, NF-κB, transcription, ankyrin, phylogeny, oncogenes, viral carcinogenesis, viral conditioning, epi-
genomics, ping-pong evolution, ASPP2, ASPP1, iASPP
Background
Analysis of viruses, mobile DNA sequences and host
genomes reveals evidence that genetic information can
be shared resulting in generation of novel hybrid
genetic elements. For example, the ubiquitous human
pathogen Epstein Barr Virus (EBV), genome structure
contains a region co-linear with the vertebrate variable
immunoglobulin gene segments including regulatory
regions for the myc oncogene, signals for immunoglo-
bulin switch recombination, somatic mutation and
coding regions[1,2]. Similarly, the EBV viral termini
contain sequences similar to somatic V(D)J immuno-
globulin and T cell receptor recombination sites and
the virus encodes a recombinase co-regulated with the
host RAG V(D)J recombinase [3-5].
These observations suggest that EBV and other DNA
viruses evolve through sharing of genetic information
with the host genome termed “Ping Pong Evolution”
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Evolution between EBV and the host immune system is
characterized. The EBV viral protein ZEBRA, Zta
encoded by BZLF-1is proposed to result from capture
and fusion of exons from two different host immune
response genes, the fos/jun transcription factor and IB
immune regulatory proteins. Analysis of host IBp r o -
teins is utilized to present an empirically testable model
of ZEBRA binding to NF-B immune response proteins
in which the unstructured carboxyl region of ZEBRA
can assume two different structural conformations when
bound to NF-B. In addition, an amino acid polymorph-
ism in this region of ZEBRA is identified that could
potentially alter the functional properties of the ZEBRA
protein interactions with both NF-B and the distantly
related tumor suppressor p53[6].
Studies of ZEBRA, the lytic switch protein, have
demonstrated that the two amino terminal exons of
ZEBRA are structurally related to the fos/jun transcrip-
tion factors and that ZEBRA binding to DNA sites,
known as ZRE, is sufficient to activate the viral lytic
cycle[7,8]. The carboxyl region of ZEBRA protein can
bind to components of the NF-B transcription family
in vitro and alter NF-Bt r a n s c r i p t i o nin vivo[9,10].
Inactivation of NF-B transcription is apparently inde-
pendent of ZEBRA’s ability to function as a transcrip-
tion factor [11-13]. It is not currently known which of
these multiple effects of ZEBRA contribute to viral car-
cinogenesis in a humanized mouse model [14].
One potential outcome of these interactions is that
inactivation of NF-B transcription during viral lytic
replication confers a selective advantage upon the virus
[15,16]. NF-B transcription factors and regulatory IB
proteins are central mediators of both the innate and
acquired immune responses [17,18]. Inactivation of NF-
B could block the innate immune response in B lym-
phocytes which are the viral host cell. Interaction
between ZEBRA and NF-B can trigger apoptosis of
cells expressing ZEBRA [19-21]. Inactivation NF-B
transcription by ZEBRA in host B lymphocytes may also
oppose the effects of latency proteins that activate NF-
B transcription, delaying apoptosis and contributing to
viral maturation and release from pre-apoptotic host
cells.
Other bystander cells such as T-lymphocytes, epithe-
lial cells and macrophages may also be transiently
infected with EBV. T lymphocytes in particular express
both the EBV CD21 receptor as well as other EBV
receptors and express ZEBRA protein [3,21,22]. Studies
of the effects of transient and stable expression of
ZEBRA in T-lymphoblastoid cell lines have confirmed
an IB-like inactivation NF-B signaling by ZEBRA and
increased T lymphocyte apoptosis [21]. Thus, an addi-
tional selective advantage of interactions between
ZEBRA and NF-B may be destruction of immune
responder cells through transient infection and
apoptosis.
Another human gamma herpesvirus, human herpes-
virus-8, first identified as the cause of Kaposi’s sarcoma,
encodes a lytic replication protein which lacks DNA
binding but has extensive amino acid similarity to
ZEBRA including the carboxyl region of ZEBRA [23-25].
This region of ZEBRA is highly conserved between dif-
ferent viral strains [26]. EBV infected lymphocytes also
express a trans-spliced ZEBRA like protein termed RAZ
sharing the carboxyl terminal NF-B binding region of
the ZEBRA protein, but lacking the ability to bind DNA
or ZRE[15,27]. RAZ is also expressed in EBV infected T
lymphocytes[3,22].
Remarkably, the carboxyl region of ZEBRA required
for interactions with NF-B transcription and ZEBRA
dimerization also binds to p53 tumor suppressor in vitro
and alters p53 transcription in vitro[28-30]. The effects
of ZEBRA on p53 transcription are stimulatory in some
cases such as T-lymphocytes and epithelial cells, but
inhibitory in B-lymphocytes[29,30]. Interactions between
ZEBRA and p53 also involve other p53 binding proteins
and are more complex than interactions in vivo between
ZEBRA and NF-B [31]. The ability of ZEBRA to inter-
act with both NF-B and p53 has previously been sug-
gested to result from a cryptic IB-like region in the
carboxyl terminus of the ZEBRA protein[6,21]. NF-B
and p53 proteins share a common IBb i n d i n gr e g i o n
because they are descendents of a common ancestral
transcription factor previously termed “proto p53/NF-
B[6]“. Since this hypothesis was proposed, the crystal
structure of ZEBRA protein has been partially solved
including a portion of the carboxyl terminus of the pro-
tein interacting with NF-B and p53[8,32]. In addition,
the interactions between p53 binding ankyrin proteins
and NF-B proteins have been characterized providing
additional evidence that regulatory proteins in the
ankyrin family, including NF-B inhibitor proteins
related to IB, bind to both NF-Ba n dp 5 3p r o t e i n s
[33].
The recently available partial structure of the ZEBRA
carboxyl terminus, and the structures of IBa and apop-
tosis-stimulating protein of p53 (ASPP2, previously
known as p53BP2) ankyrin proteins are analyzed in this
work, building on previous similarities noted between
these regulatory proteins[6].F i r s t ,i ti sd e m o n s t r a t e d
that primary amino acid similarities between the alpha
helix regions of ZEBRA and various other ankyrin pro-
t e i n sa r eu n l i k e l yt oh a v ea r i s e nb yc h a n c eo ri n d e p e n -
dent parallel evolution but instead appear to represent
capture and homologous descent of a terminal exon
encoding an IB domain by ZEBRA. Second, it is shown
that the partial crystal structure of ZEBRA is consistent
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to form an IB-like stem and loop structure. Finally,
individual ankyrin domains of IBa are shown to have
structural similarities to the ankyrins of ASPP2, and
thus able to bind to the same region targeted by ZEBRA
[6].
Methods
Definition of the ankyrin-like region of ZEBRA protein
termed “ZANK”
We previously noted that a region of ZEBRA (Figures 1,
2) has primary amino sequence similarity to IBp r i o r
to the determination of the crystal structure of ZEBRA
[6]. We first used the program PyMOL (Delano Scienti-
f i cI n c . ,C A )t od e f i n ea n dv i s u a l i z ear e g i o no fZ E B R A
whose primary amino acid sequence is similar to
ankyrin proteins [6]. ZEBRA structure was partially
solved by x-ray crystallography in 2006 and structural
coordinates are available as a protein data-base in the
public domain (2C9N.pdb). This region of ZEBRA,
termed in this work ZANK “ZEBRA ANKryn-like
region” has an alpha-helical stem and carboxyl unstruc-
tured region (Figure 1). In the course of this analysis,
The ZANK region of ZEBRA was noted to be encoded
by a single exon in all examined EBV strains coinciding
exactly with the exon-intron junction of the ZEBRA
protein third exon (Figure 2, 3). Thus, the p53 and NF-
Bb i n d i n gr e g i o n so fZ E B R A ,t e r m e dZ A N K ,w e r e
f o u n dt ob es e p a r a t eb o t hs t r u c t u r a l l ya n dg e n e t i c a l l y
from the DNA binding and trans-activation regions of
ZEBRA (Figure 4).
Alignment of ZANK with defined ankyrin proteins
ZEBRA protein and nucleotide sequences are as deter-
mined previously[26]. Individual ankyrin domains from
published IB and related sequences obtained from gen-
bank were identified using PyMOL and first aligned
with ZANK and with each other using standard algo-
rithms such as BLAST as illustrated in the text (Figure
5) Color scheme for Figure 5 can be found at http://
ekhidna.biocenter.helsinki.fi/pfam2/clustal_colours). Pre-
viously, some primary amino acid similarity between
p53 binding ankyrins, IB ankyrins, invertebrate ankyr-
ins and the ZEBRA carboxyl terminus have been illu-
strated and suggested to provide a basis for interactions
between ZEBRA and ankyrin binding proteins[6,21].
Figure 1 Structure of ZEBRA protein. The carboxyl terminus of dimeric ZEBRA protein bound to a ZRE oligonucleotide (orange) is shown. This
image was generated from previously determined ZEBRA molecular coordinates using PyMOL. The ZANK (ZEBRA ANKyrin-like region) carboxyl
terminus of ZEBRA is highlighted in blue. ZANK is composed of two regions, a highly structured alpha helix stem highlighted in darker blue (the
ZANK stem region) and a partially solved unstructured region continuing to the end of the protein highlighted in light blue (the ZANK loop
region).
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work based on previously reported optimized alignments
between the p53BP2 fragment of ASPP2 and IB. Thus,
ank3 of p53BP2 corresponds to IB ankyrin 3, p53BP2
ank4 corresponds to IBa n k y r i n4 ,a n dp 5 3 B P 2a n k 5
corresponds to IB ankyrin 5 proceeding from the amino
to carboxyl termini of both proteins respectively[6]. In a
more recent naming convention, p53BP2 which was
found to be a fragment of a larger protein known as
ASPP2 (ankyrin repeat, SH3, and proline rich domain-
containing protein number 2 also previously called apop-
tosis stimulating p53 binding protein 2) to indicate that it
is a member of a multi-protein family. Using this nomen-
clature, p53BP2 ank3 corresponds to ASPP2 ankyrin 1,
p53BP2 ank4 corresponds to ASPP2 ankyrin 2, and
p53BP2 ank5 corresponds to ASPP2 ankyrin 3 [34].
Randomization analysis of ZANK and other defined
ankyrin domains
A randomization shuffling strategy was developed to
estimate the probability that observed amino acid simila-
rities between ZANK, IB and other related ankyrins
such as invertebrate cactus and unc-22 were not
explained by the non-random amino acid composition
of ankyrin proteins. The amino acid sequence of each
ankyrin was randomized or shuffled and compared to
every other possible sequence with the number of equal
or better scores to non shuffled sequence shown.
Repeated IBa n dp 5 3 B P 2u n i t so fa n k y r i na r ec o m -
posed of a rigid alpha-helical stem and a less structured
more variable loop region that may be under different
evolutionary constraints. The borders of each ankyrin
s t e ma n dl o o pw e r ei d e n t i f i e du s i n gP y M O L( F i g u r e5 ) .
Because of this bi-partite structure, analysis of the stem
and loop regions was conducted both together and inde-
pendently (Figure 6). Randomization of 10,000 of each
stem and loop region was used in this analysis with cor-
rection for multiple comparisons. In this analysis, align-
ment of less than 500/10,000 randomized sequences is
comparable to a P value of .05, shown in yellow. Align-
ment of less than 10/10,000 sequences comparable to a
P value of .001 is shown in red.
Based on these studies the similarity between putative
ZEBRA ankyrin stem and the cactus ankyrin stems 4 is
Figure 2 Sequence and Structure of ZANK. The amino acid sequence of the unstructured loop region of ZANK (shown in light blue in Figure
1) is shown in more detail including the addition of terminal amino acids 237-245 not present in the solved structure. This region was deleted
in order to permit crystallization of the ZEBRA protein. A region with secondary structure denoted “ZANK structure” is evident in the carboxyl
terminus of ZEBRA as discussed in more detail in the text. ZANK is encoded by a discrete exon corresponding precisely with the stem and loop
regions shown in blue in Figure 1.
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and mRNA splice sites are shown. Using the same color scheme as in Figure 1, amino acids corresponding to the ZANK stem are shown in dark
blue and those corresponding to the loop region are shown in light blue. DNA sequence is derived from the B-958 strain of EBV. A single amino
acid polymorphism at aa 205 in this region has been identified resulting in a Ser substitution in certain strains of EBV such as Akata. Underlined
sequences indicate regions of the putative ZANK loop present in the crystal structure. The splice points of ZEBRA exon 3 encoding ZANK is
shown as “^” starting at the ZEBRA amino acid sequence “Val-Ala-Ala-Ala...” continuing to the end of the protein. The structured region of ZANK
loop (Figure 1, 2) corresponds to ZANK sequences 227-230 Val-Asp-Ser-Ile. Residues His239 and Phe245 in the terminus of ZANK correspond to
functionally conserved residues in the loops of other ankyrin proteins as discussed in more detail in the text.
Figure 4 A schematic diagram of the ZEBRA protein illustrating the 3 functional domains of ZEBRA. ZEBRA domains 1 and 2 contain the
transcriptional activation and DNA binding regions of the protein, respectively, and are similar to Fos/Jun transcription factors. Domain 3, the
carboxyl region of ZEBRA denoted ZANK in this work, is required for both dimerization of the ZEBRA protein as well as interactions with NF-B
and p53 transcription factors.
Dreyfus et al. Virology Journal 2011, 8:422
http://www.virologyj.com/content/8/1/422
Page 5 of 17one order of magnitude greater than other ankyrin
stems, and this relationship was maintained over a vari-
ety of Price Waterman gap values. Also highly unlikely
to occur by chance are the alignments between the
putative ZEBRA ankyrin stem and the cactus stem 2
and Bcl3 ankyrin 4 stem. In many cases individual
ankyrin stems from different ankyrin proteins such as
invertebrate cactus, IB and p53 binding protein were
more closely related than adjacent ankyrins from a sin-
gle protein, for example cactus ankyrin stem 4 and bcl3
ankyrin stem 4 are more similar than cactus ankyrin
stem 4 and other cactus ankyrins (BCL3 data not
shown). Based upon randomized sequence comparisons
shown in the ZEBRA stem-like region is most similar to
the stem region 4 of a Cactus ankyrin from the Droso-
phila fruit fly. Interestingly, the loop region of ZEBRA is
most similar to a different loop region from the cactus
protein, ankyrin 5 of cactus. However, because of the
short length o the ZEBRA stem region and other con-
founding factors such as apparent functional constraints
on stem sequence evolution it was not possible to con-
struct a unique rooted phylogeny of individual ankyrin
stems using currently available alignment software (data
not shown).
Visual inspection of individual ankyrin stem and loop
regions (Figure 5) also suggests that the loop regions of
all of the cellular ankyrins were less significantly related
either to ZEBRA or to each other except in the stem
regions. In addition, IB and cactus ankyrins follow a
pattern where alternating ankyrin loops are similar
between odd and even numbered repeats, for example
ankyrin 3 and 5 loops have more similarity in both
amino acid composition and length than to ankyrins 2
and 4 loops from both IB and cactus. Relationships
between individual ankyrin stems and loops thus appear
to represent a complicated mixture of functional con-
straints operating independently of evolutionary descent
and shared sequences conserved through descent from a
common precursor as will be analyzed in more detail
elsewhere.
In silico modeling of structural similarities between ZANK
and other defined ankyrin domains
Protein data based files of ZEBRA (2C9N.pdb), IB
bound to NF-B protein p65 (1lKN.pdb), and the
p53BP2 fragment of ASPP2 (1YCS.pdb) were used to
generate PyMOL based alignments. Experimentally
determined structures were aligned using the “align” fea-
ture of PyMOL without any operator adjustments and
using molecular coordinates as deposited in respective
pdb files without alteration of molecular coordinates.
ZANK was superimposed upon adjacent ankyrin
domains of the IBa protein initially solved as a com-
plex with NF-B p65 and the p53BP2 fragment of
ASPP2 p53 binding protein solved as a complex with
p53 (p53 structure not shown). A mechanism is pro-
posed consistent with the partial structure of ZANK
suggesting that the observed structure of ZANK could
act as a dimorphic dimer and interact with adjacent
dimorphic regions of NF-B, and also related ankyrin
binding regions of p53. IBa and IBa and p53 binding
ankyrin proteins, although not identical in primary
amino acid sequence, have remarkably similar interac-
tions with NF-B protein. This analysis is also used to
suggest a testable hypothesis where an amino acid poly-
morphism previously identified between ZEBRA protein
from Akata tumor cells and the ZEBRA protein from
non-tumorigenic B-958 could modulate the binding
interactions between ZEBRA and p53 leading to a more
cancer-promoting viral phenotype in the case of the
Akata derived ZEBRA.
Results
Identification of a structural and functional divergence
between ZEBRA carboxyl terminus and fos/jun
transcription factors
Epstein Barr Virus (EBV) encoded ZEBRA protein is
capable of switching the viral state from latency to lytic
growth through its effects on specific DNA binding sites
termed ZRE (ZEBRA Response Elements)[7]. The crystal
structure of the protein bound to a ZRE oligonucleotide
reveals similarity to Fos/Jun and other DNA binding
proteins of the BZIP transcription family as expected
Figure 5 Alignment of ZANK amino acid sequence with
vertebrate and invertebrate anykrins. ZANK amino acids present
in the solved ZEBRA structure are shown aligned with
corresponding regions of non-viral ankyrins. Alignments were
performed using clustalx, and individual vertebrate ankyrin stem
loop domains from IB, p53BP2/ASPP2, BCL3, and invertebrate
ankyrins Unc-22 and Cactus. Approximate borders of stems (s) and
loops (l) derived from PyMOL generated structures are shown at the
top of the figure. Colored regions indicate highly conserved or
identical amino acids according to the color scheme described at
http://ekhidna.biocenter.helsinki.fi/pfam2/clustal_colours.
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[8]. The structure of the carboxyl terminal region of the
ZEBRA protein has not been determined in the pub-
lished crystal structure as inclusion of this region pre-
vented protein crystallization suggesting a disordered
structure (Figure 1) [32]. This region of ZEBRA is also
dispensable for DNA binding[11].
Efforts to discover a specific mechanism for protein-
protein interactions of the carboxyl terminus region of
ZEBRA based upon the partially solved structure have
been unsuccessful, although some similarities are evi-
dent between this region and C/EBP-a, a CAAT-binding
transcription factor whose dysregulation is implicated in
acute myeloid leukemia [13]. Notably, the conserved
carboxyl terminus of ZEBRA (Figure 2) diverges from
DNA binding proteins of the BZIP family precisely at
the intron border of exon 3 (Figure 3). Like the ZEBRA
terminal exon, IB binds to both p53 and NF-B [6,21].
Exon 1 and 2 of ZEBRA thus encode a Fos/Jun homolo-
gue that activates DNA transcription to initiate the viral
lytic program, while exon 3 (shared with trans-spliced
RAZ protein) provides both protein self-dimerization
and binding to other master regulatory transcription fac-
tors such as p53 and NF-B. These observations are
analyzed in more detail in the remainder of this work.
ZANK, the carboxyl terminal Zebra ANKyrin-like region
Interactions between ZEBRA and NF-B, p53 as well as
other proteins can occur independently of ZEBRA DNA
binding, since experiments in vivo have shown that in
T-lymphocytes ZEBRA is not bound to DNA but loca-
lized to the cytoplasm where it blocks NF-B transloca-
tion to the nucleus [6,21]. The full sequence of the
carboxyl terminus exon (exon 3) of ZEBRA is shown in
Figure 2, including both regions of the protein present
in the crystal structure (blue highlights in Figure 1) and
extreme carboxyl residues not present in the crystal
s t r u c t u r e[ 2 6 ] .W ep r e v i o u s l ys u g g e s t e dt h a tt h ec a r -
boxyl terminus of ZEBRA encodes an ankyrin-like struc-
ture responsible for the ability of ZEBRA to bind
ankyrin binding proteins NF-Ba n dp 5 3[ 6 , 2 1 ] .F o r
purposes of discussion, the carboxyl terminus of ZEBRA
Figure 6 Statistical analysis of ZANK amino acid sequence similarity to other ankyrins. Representative results of shuffling experiments for
ZANK, vertebrate ankyrins, IBa, p53BP2/ASPP2 ankyrins, and invertebrate ankyrins Cactus and Unc-22 are shown. Top: Randomizations of whole
ankyrin repeats. Middle: ankyrin stem regions only. Bottom: ankyrin loop regions only. 10,000 randomly shuffled sequences of identical amino
acid composition were generated in each cell. Shuffled sequences were aligned with indicated non-shuffled sequence and the number of scores
greater than or equal to that of the non-shuffled input sequence is shown.. Significant alignments (p < 0.05) are shown highlighted in yellow
while highly significant alignments (p < 0.001) are shown highlighted in red.
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ANKyrin-like region) in the remainder of this work.
Remarkably, the crystal structure of ZEBRA protein
(Figure 1) shows divergence from BZIP Fos/Jun DNA
binding proteins precisely at the intron/exon borders of
ZEBRA exon 3 (Figure 2, 3).
Comparison of ZANK with defined vertebrate and
invertebrate ankyrin domains
ZANK spans part of the alpha helix of ZEBRA and
unstructured regions at the carboxyl terminus of the
protein (Figure 3, 4). The alpha-helical stem-like regions
contribute most of the similarity between ZANK and
individual ankyrins (Figure 5). This is evident in Figure
5 because most of the colored coded similar regions
occur to the left of the figure in the stem regions
(denoted s) rather than the loop regions (denoted l).
This was confirmed by a randomization analysis (Figure
6). Randomizations demonstrate that the full ZANK
sequence or loop region results in less significant align-
ments or no significant alignments for both ZANK and
other ankyrins compared to randomization of the stem
regions (Figure 6). The alpha helical regions of ankyrin
binding proteins are highly structured to provide a rigid
framework, while the loop regions are less structured
allowing for binding to different substrates. Results are
consistent with the hypothesis that ZANK encodes
amino acids derived from a common ancestral ankyrin
domain shared with IB and p53 binding ankyrins and
are most closely related to the invertebrate Drosophila
ankyrin regulatory protein Cactus, rather than vertebrate
ankyrins.
Statistical significance as highlighted in yellow in Fig-
ure 6 is defined as a given alignment found in less than
5% of shuffled sequences (less than 500 out of 10,000),
corresponding to P < 0.05 that the alignment would
occur by chance. A more stringent definition of a non-
random alignment (highlighted in red in Figure 6) is
defined as a given alignment found in less than 0.1% of
shuffled sequences (less than 10 out of 10,000). In all
cases analyzed, including ZANK, the stem or alpha helix
regions of ankyrins are more conserved across ankyrin
protein families than the loop regions. For example, not
all IBa loops in host proteins are similar to each other,
but all the IBa stem regions are similar based upon
10,000 random shuffling of the respective sequences.
The diagonal of each randomization experiment
shown is the identity of the sequence with itself shown
in red, which as expected, occurs once per 10,000 shuf-
fling experiments. Because each cell represents a charac-
terization of an independent shuffling “experiment” the
number of aligned sequences are slightly different even
for identical comparisons as can be seen by comparing
identical comparisons on either side of the diagonal
identity but because of the large number of shuffling per
“experiment” results are usually similar for a given cell
on either side of the diagonal.
ZANK is more similar to an invertebrate ankyrin domain
from Cactus than vertebrate ankyrins
As shown in Figure 6, the ZANK stem was most similar
to the ankyrin 4 stem region of invertebrate Drosophila
Cactus regulatory protein at the highest level of signifi-
cance (less than 10/10,000 of shuffled sequences).
ZANK loop was most similar to invertebrate Drosophila
Cactus regulatory protein ankyrin 5 loop region at the
highest level of significance (less than 10/10,000 of
shuffled sequences). Similarity was also evident between
ZANK and the Cactus regulatory protein ankyrin 2 stem
region and the IBa ankyrin 3 and 5 stems as well as
the whole protein. Similarity to both stem and loop
regions of Cactus in addition to elements of IBa is a
surprising result since EBV is a vertebrate pathogen,
while Cactus is an invertebrate host gene, suggesting
that the divergence of ZANK from other ankyrins was
ancient, possibly preceding divergence of p53 and NF-
B ankyrin binding proteins such as IBa. Alternatively,
a vertebrate virus encoding ZANK could have resulted
from recombination with an invertebrate Drosophila
virus since in some cases insect viruses can infect verte-
brate cells. Existing phylogeny programs do not appear
able to resolve these two possibilities as will be dis-
cussed in more detail elsewhere.
In silico Modeling of ZANK
In the remainder of this work we used PyMOL gener-
ated structures to model experimentally observed bind-
ing between ZEBRA protein and both NF-Ba n dp 5 3
in vitro and in vivo. A limitation of this analysis is that
the existing structure of ZANK is both partial and also
solved in the absence of the partner ligands p53 or NF-
B. However, even with those limitations this analysis is
sufficient to suggest a model of ZANK interactions with
its partner ligands in which the ZANK loop adopts two
different conformations. We have previously suggested
that binding between ZEBRA carboxyl terminus and
other proteins can be explained by the common descent
of both NF-B and p53 from an ancestral protein
termed proto-p53/NF-B. If this hypothesis is correct
then it should be possible to identify a common struc-
tural signature or code between ZANK, NF-Bb i n d i n g
ankyrins and p53 binding ankyrins that ZANK has
evolved to fit into. To use an analogy, if ankyrins resem-
ble a key that can bind to their substrates resembling a
lock, then the ZANK key should fit into both the NF-
B and p53 locks[6,21].
To explore the possibility of this “lock and key”
mechanism, IBa ankyrin structures were extracted and
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the solved crystal structure coordinates. Since ZEBRA
protein exists as a dimer of identical subunits (Figure 1),
two adjacent ZANK loop domains in the dimerized
ZEBRA protein could interact with adjacent IBa
ankyrin binding regions of NF-B. As shown, Ank 3
and 4 of IBa p l a yac r i t i c a lr o l ei nI Ba interactions
with NF-B (Figure 7). In support of this hypothesis,
residues such as Histamine 239 in ZANK (Figure 3), not
present in the crystal structure of ZEBRA due to
instability in the absence of either co-ligand NF-Ba n d
tumor suppressor p53, could align with a corresponding
conserved stem histidine in IBa A n k3a n dr e l a t e d
ankyrin proteins (Figure 5). Binding to proteins such as
NF-B and p53 could stabilize ZANK and permit a
crystal or structure to confirm this model.
NF-B binding ankyrins have an alternating key or code
of short and long ankyrin loops suggesting a
polymorphic ZANK loop domain
Ankyrin loop regions are variable in length while the
stems are conserved in length (Figure 5). There is an
alternating pattern of short loops (approximately 15
amino acids between adjacent stems) and long loops
(approximately 20 amino acids between adjacent stems)
in all of the NF-B binding ankyrins including verte-
brate IBa and invertebrate cactus. Thus both IBa and
cactus ankyrin loops 2, 4, and 6 are short and loops 1,
3, and 5 are long. To permit binding interactions with
NF-B, the ZANK loop region of ZANK would need to
be dimorphic or sufficiently unstructured or flexible to
conform to adjacent non-identical short and long
ankyrin binding pockets in NF-B, for example the
regions of NF-B binding to Ankyrins 3 and 4 of IBa
as shown (Figure 7, 8, 9). Because the ankyrin loops of
IBa ank5 are very similar in both primary and second-
ary structure to IBa ank3, IBa has an alternating pat-
tern of Ank3 and Ank4-like subunits, and this
alternating structure could permit multiple ZANK bind-
ing sites in a single NF-kb ligand (Figure 10).
Also resulting from this alternating short loop/long
loop pattern, using PyMOL generated structures it is
evident that IBa ankyrin 3 has additional amino acids
in its loop region forming a bulge not present in ankyrin
Figure 7 Illustration of the Interaction of IBa ankyrins with NF-B.N F - B p65/p50 dimer subunits (red shadings) are shown bound to
ankyrin repressor IBa.I Ba ankyrin domains 3 (green) and 4 (yellow) are shown in color while other regions of the IBa protein are shown in
grey. Each ankyrin unit is composed of a structurally conserved alpha helix dimer backbone, and a less structurally conserved loop region
inserting into the NF-B p65/p50 groove.
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present in ankyrin 4 (Figure 9). If ZEBRA were to bind
to both IBa ankyrin 3 and 4 binding regions in NF-B,
ZANK would need to adapt 2 different conformations
to fit into the two different sites, for example by having
free amino acids outside of the binding region at the
Ankyrin 4 site, while utilizing additional amino acids in
the extreme carboxyl region of the ZEBRA protein in
the deeper Ankyrin 3 site. The bulge region present
both ankyrin 3 and 5 loops is not present in ankyrin 4
loop (Figure 10), but corresponds to a structured region
of the ZANK loop (Figure 9). In the IBa structure,
these structured regions of are proposed to form a a
helix like region stabilizing the IBa loops.
Shared structural elements between p53 and NF-kB
binding ankyrins identified as a potential binding
mechanism of ZANK
We suggested previously that that the ability of ZEBRA
to bind both NF-B and p53 results from an
Figure 8 Alignment of IBa Ank3 and Ank4 Helices.I Ba Ank3 (green) and Ank4 (yellow) domains are extracted from the NF-Bp 6 5 / p 5 0
dimer bound structure and are shown superimposed to illustrate the highly conserved structure of the stem and the less conserved loop region.
Ank3 loop has a bulge not present in Ank4. Ank3 also has more bulky hydrophobic residues than Ank4 in the region of the loop extending most
deeply into the NF-B p65/p50 structure. Arrows illustrate key features of Ank3 and Ank4 including a highly conserved His residue shared by most
ankyrin stems (Ank3, His 149; Ank4, His 188). Also shown are bulky residues in Ank3 (Tyr 181 and His184) present in Ank4.
Figure 9 Alignment of ZANK Loop with IBa Ank3 and Ank4.
The structure of ZANK loop (light blue) is superimposed on IBa
Ank3 (green) and Ank4 (yellow) structures. The structured region
present in ZANK loop overlaps the bulge of Ank3, not present in
Ank4. Like Ank4, ZANK has no significant hydrophobic regions in
the solved structure, but ZANK extends further due to unstructured
residues not present in the solved structure (Figure 2).
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the two proteins[6,21]. The solved structure of p53bp2
(more recently denoted ASPP2 (1YCS.pdb)) bound to
p53 demonstrates that p53bp2/ASPP2 contacts p53 in
only the extreme carboxyl terminus, ankyrins 4 and 5,
of its ankyrin regions, although other binding modes
could exist in vivo. Pymol generated alignment between
IBa ankyrin 3 and p53bp2/ASPP2 ankyrin 5 is shown
(Figure 11). p53bp2/ASPP2 ankyrin 5 has a structure
with features similar to IBa ankyrin 3 – ah i g h l yc o n -
served tyrosine is shared between ankyrin 3 and ASPP2
ankyrin 5, and this residue in IBa is known to form a
specific contact with a tyrosine in NF-B p50/p65
dimer. Interestingly, the p53bp2/ASPP2 ankyrin loops
do not have a short long loop pattern (Figure 5) but
instead have a length corresponding to the short IBa
ankyrin loops (approximately 15 aa), and a conserved
tyrosine typical of the long loops. These observations
are consistent with a shared binding signature between
some NF-B and p53 binding proteins that could be tar-
geted by a polymorphic ZANK loop as a master key.
Identification of a cancer associated sequence variant in
ZANK potentially altering p53binding interactions
An advantage of PyMOL generated in silico structural
analysis of ankyrin domains in NF-B proteins and p53
binding proteins is that it may now possible to predict
the behavior of polymorphisms in ZEBRA that increase
Figure 10 Structurally similar large ankyrin loops alternate with small ankyrin loops in IBa.I Ba Ank3 (green) is shown superimposed
on IBa Ank5 (light green) to illustrate corresponding structural features. Alternating small and large ankyrin loops seem to be a conserved
feature of vertebrate and invertebrate NF-B binding ankyrins, suggesting a “lock and key” mechanism. ZEBRA is proposed to mimic both large
ankyrin loop structures and small ankyrin loop structures in order to fit into the NF-B binding code. The bulge region of Ank3 and Ank5,
although encoded by different primary amino acids both can form a structure corresponding to the helix structure found in ZANK (Figure 9).
IBa Ank3, Ank5, and potentially ZANK, also share conserved orientation of aromatic and bulky amino acids in the loop regions not present in
IBa Ank4.
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versus p53 proteins (Figure 12). Alterations in ZANK
amino sequences could alter the ability of ZEBRA to
transiently block p53 function during viral replication
and thus alter viral growth properties, accounting in
part for the recently described association of ZEBRA
with increased mutagenic and carcinogenic properties in
a murine model[14]. For example, the limited sequence
polymorphism data available for the ZANK region of
ZEBRA currently suggests that a mutation in tumor
associated ZEBRA from Akata cells is different from
canonical B-958 ZEBRA at a single amino acid in the
ZANK region (ZEBRA exon 3). Remarkably, primary
sequence comparison between ZANK, IBa n dr e l a t e d
proteins and ASPP2 ankyrins reveals that the substitu-
tion of a serine for an alanine at amino acid 205 (Figure
3) is not random but rather converts ZANK from an
IB-like AAA motif to a p53BP2/ASPP2-like ASA motif,
also shared with a Cactus ankyrin (Figure 5). Unlike ala-
nine, a serine residue may be covalently modified in vivo
by phosphorylation, further extending the possible func-
tional consequences of this polymorphism[35]. These
observations suggest further study of ZANK polymorph-
isms in vivo and their effects on NF-B and p53 binding
Figure 11 Alignment of IBa Ank3 and p53BP2/ASPP2 Ank5 structures are consistent with a shared binding mechanism between NF-
B binding ankyrins and p53 binding ankyrins that could be targeted by ZANK.I Ba Ank3 (green) is shown superimposed on p53bp2/
ASPP2 Ank5 (Salmon). P53bp2/ASPP2 Ank5 is similar in length to NF-B binding short ankyrin loops but also shares structural features spatially
conserved in location and orientation to long ankyrin loops such as IBa Ank3. p53BP2/ASPP2 Ank5 aa Tyr 424 aligns structurally a with IBa
Ank3Tyr 181 (filled blue arrow). The terminal residue of ZANK (Tyr 245) could substitute for highly conserved aromatic tyrosine binding
interaction between IBa Ank3 tyr 181 and NF-B, as well as coordinating corresponding interactions between ZANK and p53. Both short and
long ankyrins and P53bp2/ASPP2 Ank5 share a highly conserved histidine corresponding to IBa Ank3 aa His 149 (dark blue arrow). A
corresponding residue is present in ZANK (Val 203). P53bp2/ASPP2 Ank5 lacks a residue corresponding to IBa Ank3 aa His 184 (narrow stem
blue arrow), but a corresponding residue (His 239) is present in ZANK.
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strain polymorphisms and cancer phenotypes.
A model of antagonistic interactions between ZANK NF-
B and p53 protein binding and ZEBRA fos/jun DNA
binding
As outlined in this manuscript, the extreme carboxyl
terminal exon of ZEBRA encodes an amino acid
sequence termed ZANK that is functionally and evolu-
tionarily distinct from DNA binding regions of ZEBRA
protein. The distinct origin and structure of ZANK sug-
gest that ZANK domain could have a regulatory role on
the DNA binding regions of the ZEBRA protein in addi-
tion to cytoplasmic effects on NF-Ba n dp 5 3p r o t e i n s
(Figure 1). In particular, ZANK could modulate ZEBRA
DNA binding through conformational changes in the
Fos/Jun like region of ZEBRA (Figure 4) triggered by
binding between ZANK and proteins of the NF-Ba n d
p53 family and vice versa, modulating the transcriptional
activity of the cellular transcription machinery (Figure
13).
Binding of ZANK to proteins of the NF-Ba n dp 5 3
families could stimulate, inhibit or have no effect of
ZEBRA binding to DNA. As shown in Figure 13, struc-
tural considerations based on the partial structure of
ZEBRA and ZANK support an antagonistic role between
ZEBRA DNA binding and ZANK interactions with NF-
B and p53 proteins. Based upon the crystal structure
of ZEBRA bound to a ZRE/AP1 DNA binding oligonu-
cleotide (Figure 1), it is apparent that DNA bound to
ZEBRA causes the two DNA binding alpha helices to
move away from each other. The movement of the
ZANK regions at the termini of the helices in a region
not bound to DNA is analogous to the blades of a scis-
sor in the open position. A parallel orientation of the
ZANK stems, similar to the closed blades of a scissor is
required to form an ankyrin-like dimer capable of bind-
ing adjacent regions of NF-B and p53 proteins (Figure
7).
Thus, ZANK could function as a NF-B and p53 pro-
tein dependent switch in the nucleus of EBV infected B-
lymphocytes, turning ZEBRA DNA binding off in the
presence of high levels of nuclear NF-Ba n dp 5 3 ,a n d
conversely activating ZEBRA DNA binding in the
absence of nuclear NF-B and p53 protein (Figure 13).
In physiologic terms, these observations are consistent
with high levels of active NF-B and p53 proteins pre-
sent in the nucleus of latent B-lymphocytes during viral
latency, which during viral latency would tend to block
ZEBRA DNA binding and prevent activation of viral
lytic growth. Conversely, transiently decreased levels of
nuclear NF-B proteins in latently infected B-
Figure 12 ZANK Structure with S205A polymorphism illustrated. A functionally conserved polymorphism in ZANK, A205 is altered to Ser is
present in some EBV positive lymphoma cell lines such as Akata. A similar serine rather than alanine residue is present in some p53 binding
protein ankyrin domains but not in NF-B binding ankyrin domains. Changes in the stem or loop regions of ZANK could alter ZANK loop
interactions with p53 and NF-B particularly if covalently modified by serine phosphorylation. The circled region indicates a potential interaction
between ZANK stem and loop amino acids.
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could permit increased ZEBRA DNA binding and acti-
vation of viral lytic growth, coupling levels of cytoplas-
mic growth signals mediated by NF-Ba n dp 5 3
proteins to the viral life cycle.
Later in the viral lytic replication cycle, the NF-B and
p53 protein binding function of ZANK could further
trigger cellular apoptosis and facilitate infectious viral
release directly through cytoplasmic effects on NF-B
and p53 protein. In T lymphocytes and possibly other
non B-lymphocyte cells infected by EBV but incapable
of supporting stable viral latency, ZEBRA is almost
entirely present in the cell cytoplasm. In these cells,
ZEBRA could initially inhibit NF-B and cause activa-
tion of p53 protein and cellular apoptosis as a mechan-
ism of viral immunosuppression.
Transpliced RAZ, containing ZANK but not capable
of ZEBRA DNA binding would then serve as an ampli-
fier of the NF-B and p53 protein functions of ZEBRA,
and a corresponding RAZ-like function might explain
the non-DNA binding functions of a ZEBRA homologue
in HSV-8, the etiologic agent of Kaposi’s sarcoma and
other human cancers. These possibilities could in princi-
p l eb et e s t e din vitro and in vivo through ZEBRA with
ZANK domains engineered for either increased or
reduced effects on NF-Ba n d / o rp 5 3p r o t e i nt h r o u g h
mutation of conserved ZANK amino acids interacting
with NF-B and p53 protein identified with the struc-
tural models and analysis presented in this work.
Conclusions
Characterization of B cell lympho-proliferative disorders
haa demonstrated that EBV viral latency proteins can
transform and immortalize B-lymphocytes in vitro and
in vivo. A causal role of the virus in carcinogenesis is
suggested in some tumors because the viral genome
sometimes remains in the malignant cell. However, the
mechanism of viral carcinogenesis cannot simply be a
function of cellular immortalization by the virus since
although the vast majority of humans harbor EBV
immortalized B lymphocytes, EBV-genome associated
cancers are rare [36]. EBV infection may thus also be
associated with carcinogenesis not only through cellular
immortalization but also through transient mechanisms
including destabilization of host genomes[37-40].
A novel role of ZEBRA and ZANK in viral carcino-
genesis is suggested in this work. ZEBRA plays a critical
role in the viral latent to lytic switch, possibly in part
through response to NF-B and p53 activities by ZANK
(Figure 13). Alternating cycles of partial lytic growth
triggered by ZEBRA activation and ZEBRA DNA bind-
ing followed by ZANK interactions with NF-B and p53
could synergize with genomic instability contributed by
cellular or viral recombinase activation in EBV infected
cells. Partial cycles of viral activation and inactivation
without completion of the viral life cycle could be parti-
cularly relevant in the “hit and run” scenario, proposed
for viral carcinogenesis and immune dysregulation as
proposed in epithelial breast cancers [41-47].
Notably, it is possible that viral inactivation of p53 ori-
ginates indirectly or as an evolutionary “spandrel.” A
spandrel refers to a new phenotype generated by altera-
tion of a related developmental pathway. Because of the
evolutionary relationship between NF-Ba n dp 5 3
through descent from a common ancestral transcription
factor, an unavoidable consequence of the inactivation
of NF-B by an ankyrin-like region of ZEBRA is a span-
drel-like transient inactivation of p53. Restated, the
common origins of NF-B and p53 conserve a similar
ankyrin binding region in both proteins, so any viral
protein that targets this site on NF-Bp r o t e i n sc o u l d ,
in parallel, affect p53 generating new p53 dependent
phenotypes. This may in part contribute to the selective
loss of the IBa locus in tumors, a conserved feature of
several EBV associated tumors[48,49]. The ZANK span-
drel effects on p53 are maintained because of a selective
benefit to the virus from related transient inactivation of
the NF-B transcription family and the innate immune
system, as well as effects of ZANK on regulation of
ZEBRA DNA binding.
Figure 13 ZANK Ankyrin Switch Model. ZEBRA is proposed to
have two distinct conformations depending on subcellular
localization and DNA-binding. Left: When ZEBRA is bound to ZRE or
AP-1 sites on DNA the two alpha helix strands are forced apart
similar to the blades of an open scissors, preventing alignment of
ZANK domains. Right: When ZEBRA is not bound to DNA either
because of its cytoplasmic location or due to its binding to NF-B
and/or p53 proteins, the two alpha helices of the ZEBRA dimer can
adopt a parallel or closed conformation similar to the parallel
helices of ankyrin bound to NF-B and/or p53 protein.
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genes because their presence was associated with tumor
phenotypes including tumor growth and resistance to
apoptosis[50-52]. Surprisingly, wild type p53 was later
shown to be a tumor suppressor through the effects of
the protein as a DNA-binding transcription factor,
rather than a tumor promoter. These contradictory
effects could result from opposing tumor promoting
spandrel effects between numerous viral proteins such
as ZEBRA and mutant p53 proteins, versus tumor sup-
pressing DNA binding gene activation by wild type p53
protein. Thus ZANK might augment the effects of
mutant p53, not directly related to p53 DNA binding,
but rather due to effects on structurally similar regions
of NF-B proteins required for cellular proliferation.
From an evolutionary perspective, it is likely that EBV
encoded ZEBRA protein and a related protein in
Human Herpes Virus 8 diverged from other BZIP DNA
binding proteins such as Fos/Jun through viral capture
of a terminal exon encoding a single ankyrin-like stem
and loop. This domain was capable of dimerization into
a structure resembling adjacent IB ankyrins, and was
subject to positive selection through interactions with
NF-B proteins. However, because of the shared ankyrin
binding domain between NF-Ba n dp 5 3p r o t e i n sa n
unfortunate consequence of NF-B inhibition by ZANK
would also unavoidably be inactivation of p53. This
could be particularly important as a pathogenic mechan-
ism of EBV-related genomic instability in epithelial cells
and T lymphocytes that do not support the establish-
ment of viral latency or replication but can sustain a
limited form a viral lytic growth that includes high levels
of expression of a trans-spliced protein “RAZ” contain-
ing ZANK, but without the DNA-binding transcriptional
activity on ZRE. In this context, these cells are “dead
end hosts” in their inability to support viral replication
but can nevertheless suffer the pathophysiological and
molecular consequences of viral infection.
Viral pre-conditioning by common viral pathogens has
been indirectly implicated in the clustering of human
cancers both geographically and temporally based upon
indirect evidence in human cancers that defective or
abortive replication of common viral pathogens can
account for clustering of cancers[53]. In the “viral condi-
tioning” scenario, abortive cycles of viral replication can
promote genomic instability. A model is presented here
for the specific case of EBV. In the case of EBV and,
potentially, other common viruses that interact with
both NF-B and p53, transient lytic gene expression in
both B lymphocytes and non-B cells could provide a
mechanism for this viral pre-conditioning where defec-
tive or aborted viral replication contributes to malig-
nancy as supported by indirect epidemiologic evidence
[54-56]. These effects of ZANK could be of particular
importance not only in B lymphocytes but in epithelial
and T cell infection in which the virus expresses lytic
gene products but in most cases does not establish
latency[57]. In these cell types transient inactivation of
the tumor suppressor p53 would occur in the context of
activation of endogenous somatic recombination path-
ways, potentially resulting in re-arrangement, instability
and mutation of endogenous oncogenes.
In summary, we have demonstrated that ZEBRA is a
hybrid protein resulting from viral capture of both a
Fos/Jun like transcription factor and a polymorphic IB-
like ankyrin carboxyl terminus. Primary sequence and
structural similarities are evident between the carboxyl
terminus of ZEBRA protein and the conserved stem
regions of IBa and p53BP2/ASPP2 ankyrins. It is sug-
gested that a shared binding pocket in NF-B is in turn
bound by all of these ankyrin proteins and that ZANK
is analogous to a “master key” capable of fitting into
both NF-Ba n dp 5 3p r o t e i n“locks”.I nt h ec a s eo f
ZEBRA, protein binding to NF-Bp r o v i d e sas e l e c t i v e
advantage to the virus through inactivation of the
immune response against the virus during viral lytic
replication, simultaneously and unavoidably altering the
activation of p53.
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